Chief Medical Officer, Boehringer Ingelheim
Mehdi Shahidi is Chief Medical Officer (CMO) and Corporate Senior Vice President Medicine at Boehringer Ingelheim. He studied Medicine in Tehran and completed his specialist training in Clinical Oncology at the Royal Marsden Hospital in London. He was a senior clinical research fellow at the Institute of Cancer Research in London for 5 years before joining the pharmaceutical industry. He held positions as Medical Director of Oncology at PRA International and Medical Expert, Oncology at Novartis UK before joining Boehringer Ingelheim. At Boehringer Ingelheim, Dr Shahidi led the clinical development program of afatinib from phase I through phase III including the successful global filing and registration. Over years he assumed broader responsibilities across clinical development and medical affairs in Boehringer Ingelheim and became Global Head of Medicine, Oncology in 2016 overseeing Clinical Development and Medical Affairs of the entire portfolio of BI oncology compounds. Since March 2019, he assumed his current role as CMO of Boehringer Ingelheim.